Astellas Pharma, Inc./ US04623U1025 /
06/09/2024 21:59:57 | Chg. -0.0600 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
12.4000USD | -0.48% | 60,205 Turnover: 700,778.2285 |
-Bid Size: - | -Ask Size: - | 21.22 bill.USD | - | - |
Assets
|
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
|||
---|---|---|---|---|---|
Property and Equipment | 269,044 | 286,459 | |||
Intangible Assets | 623,431 | 562,496 | |||
Long-Term Investments | - | - | |||
Fixed Assets | 1.41 mill. | 1.41 mill. | |||
Inventories | 153,072 | 174,386 | |||
Accounts Receivable | 412,258 | 452,138 | |||
Cash and Cash Equivalents | 315,986 | 376,840 | |||
Current Assets | 923,354 | 1.05 mill. | |||
Total Assets | 2.33 mill. | 2.46 mill. |
Liabilities
|
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
|||
---|---|---|---|---|---|
Accounts Payable | 131,415 | 144,453 | |||
Long-term debt | - | - | |||
Liabilities to Banks | - | - | |||
Provisions | 28,224 | 30,440 | |||
Liabilities | 872,087 | 948,564 | |||
Share Capital | - | - | |||
Total Equity | 1.46 mill. | 1.51 mill. | |||
Minority Interests | - | - | |||
Total liabilities equity | 2.33 mill. | 2.46 mill. |
Income Statement
|
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
|||
---|---|---|---|---|---|
Revenues | 1.3 mill. | 1.52 mill. | |||
Depreciation (total) | 28,283 | 38,436 | |||
Operating Result | 155,686 | 133,029 | |||
Interest Income | 1,200 | -669 | |||
Income Before Taxes | - | - | |||
Income Taxes | 32,800 | 33,647 | |||
Minority Interests Profit | - | - | |||
Net Income | 124,086 | 98,714 |
Per Share
Cash Flow
|
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
|||
---|---|---|---|---|---|
Cash Flow from Operating Activities | 257,444 | 327,767 | |||
Cash Flow from Investing Activities | -62,413 | -84,500 | |||
Cash Flow from Financing | -216,298 | -195,623 | |||
Decrease / Increase in Cash | - | - | |||
Employees | 14,520 | 14,480 |